MEDIPEEL Appoints Jason Wi as New CEO
South Korean skincare company MEDIPEEL has appointed industry veteran Jason Wi as its new Chief Executive Officer. Wi is tasked with leading the company's international expansion and driving global operational excellence. The appointment is part of an operational transformation aimed at enhancing the brand's reputation.
Jason Wi's appointment signals a strategic pivot by majority owner Morgan Stanley Private Equity Asia, prioritizing operational and investment discipline over a traditional beauty industry background. His experience at McKinsey & Company and SoftBank Ventures Asia points to a focus on scaling high-growth companies and expanding K-culture ventures globally, a playbook now being applied to MEDIPEEL. This move is common in private equity, where external CEOs are hired in 75% of portfolio companies to drive rapid transformation. The new strategy marks a shift from a conventional export-heavy model to a localized, partnership-driven approach to build a more resilient and agile global operation. For private equity-backed CEOs, this urgency to restructure is paramount, with an emphasis on leaders who can act decisively to cut costs and grow revenue quickly to meet demanding investor timetables. Wi's focus is on establishing an "institutionalized operating system" to sustain the brand's growth. Wi plans to integrate AI and data-driven methods from his time in the tech and investment sectors to enhance MEDIPEEL's core business. Key initiatives include optimizing supply chain management and improving customer engagement to boost long-term efficiency. This aligns with broader beauty industry trends, where AI is increasingly used for trend prediction, personalizing product recommendations, and data-driven inventory management. This leadership change occurs as the global dermocosmetics market is projected to grow significantly, with one forecast predicting a CAGR of 9.5% from 2025 to 2031. The K-beauty market specifically is set for rapid expansion, estimated to climb from US$17.1 billion in 2026 to US$34.6 billion by 2033. MEDIPEEL's strategy will be tested in a competitive landscape where the US has overtaken China as the top export destination for K-beauty.
